510 related articles for article (PubMed ID: 26519985)
1. Future directions in risk stratification and therapy for advanced pediatric genitourinary rhabdomyosarcoma.
Harel M; Ferrer FA; Shapiro LH; Makari JH
Urol Oncol; 2016 Feb; 34(2):103-15. PubMed ID: 26519985
[TBL] [Abstract][Full Text] [Related]
2. Focusing on organ preservation and function: paradigm shifts in the treatment of pediatric genitourinary rhabdomyosarcoma.
Shapiro DD; Harel M; Ferrer F; McKenna PH
Int Urol Nephrol; 2016 Jul; 48(7):1009-13. PubMed ID: 27068815
[TBL] [Abstract][Full Text] [Related]
3. [Clinical and prognostic analysis of single-center multidisciplinary treatment for rhabdomyosarcoma in children].
Xu N; Duan C; Jin M; Zhang DW; Su Y; Yu T; He LJ; Fu LB; Zeng Q; Wang HM; Zhang WP; Ni X; Ma XL
Zhonghua Er Ke Za Zhi; 2019 Oct; 57(10):767-773. PubMed ID: 31594063
[No Abstract] [Full Text] [Related]
4. Genitourinary rhabdomyosarcoma: which treatment, how much, and when?
Wu HY; Snyder HM; Womer RB
J Pediatr Urol; 2009 Dec; 5(6):501-6. PubMed ID: 19640790
[TBL] [Abstract][Full Text] [Related]
5. Pediatric urologic rhabdomyosarcoma.
Stehr M
Curr Opin Urol; 2009 Jul; 19(4):402-6. PubMed ID: 19440152
[TBL] [Abstract][Full Text] [Related]
6. Pediatric urologic oncology.
Grimsby GM; Ritchey ML
Pediatr Clin North Am; 2012 Aug; 59(4):947-59. PubMed ID: 22857841
[TBL] [Abstract][Full Text] [Related]
7. Rhabdomyosarcoma: an overview.
Dagher R; Helman L
Oncologist; 1999; 4(1):34-44. PubMed ID: 10337369
[TBL] [Abstract][Full Text] [Related]
8. DNA content and proliferative activity in pediatric genitourinary rhabdomyosarcoma.
San Miguel-Fraile P; Carrillo-Gijón R; Rodríguez-Peralto JL; Ortiz-Rey JA; Alvarez-Alvarez C; de la Fuente-Buceta A
Pediatr Pathol Mol Med; 2003; 22(2):143-52. PubMed ID: 12556294
[TBL] [Abstract][Full Text] [Related]
9. Comparison of outcomes based on treatment algorithms for rhabdomyosarcoma of the bladder/prostate: combined results from the Children's Oncology Group, German Cooperative Soft Tissue Sarcoma Study, Italian Cooperative Group, and International Society of Pediatric Oncology Malignant Mesenchymal Tumors Committee.
Rodeberg DA; Anderson JR; Arndt CA; Ferrer FA; Raney RB; Jenney ME; Brecht IB; Koscielniak E; Carli M; Bisogno G; Oberlin O; Rey A; Ullrich F; Stevens MC; Meyer WH
Int J Cancer; 2011 Mar; 128(5):1232-9. PubMed ID: 20473932
[TBL] [Abstract][Full Text] [Related]
10. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
Meza JL; Anderson J; Pappo AS; Meyer WH;
J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and Management of Rhabdomyosarcoma in Children and Adolescents: ICMR Consensus Document.
Panda SP; Chinnaswamy G; Vora T; Prasad M; Bansal D; Kapoor G; Radhakrishnan V; Agarwala S; Laskar S; Arora B; Kaur T; Rath GK; Bakhshi S
Indian J Pediatr; 2017 May; 84(5):393-402. PubMed ID: 28378141
[TBL] [Abstract][Full Text] [Related]
12. Rhabdomyosarcomas and other soft tissue sarcomas in pediatric patients.
Parham DM
Curr Opin Oncol; 1993 Jul; 5(4):672-7. PubMed ID: 8364084
[TBL] [Abstract][Full Text] [Related]
13. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
[TBL] [Abstract][Full Text] [Related]
14. Pediatric genitourinary tumors.
Merguerian PA
Curr Opin Oncol; 2003 May; 15(3):222-6. PubMed ID: 12778016
[TBL] [Abstract][Full Text] [Related]
15. Pediatric genitourinary tumors.
Angell SK; Pruthi RS; Merguerian PA
Curr Opin Oncol; 1996 May; 8(3):240-6. PubMed ID: 8804811
[TBL] [Abstract][Full Text] [Related]
16. Pediatric genitourinary tumors.
Merguerian PA; Chang B
Curr Opin Oncol; 2002 May; 14(3):273-9. PubMed ID: 11981271
[TBL] [Abstract][Full Text] [Related]
17. Significance of fusion status, Oberlin risk factors, local and maintenance treatment in pediatric and adolescent patients with metastatic rhabdomyosarcoma: Data of the European Soft Tissue Sarcoma Registry SoTiSaR.
Heinz AT; Schönstein A; Ebinger M; Fuchs J; Timmermann B; Seitz G; Vokuhl C; Münter M; Pajtler KW; Stegmaier S; von Kalle T; Kratz CP; Ljungman G; Juntti H; Klingebiel T; Koscielniak E; Sparber-Sauer M;
Pediatr Blood Cancer; 2024 Jan; 71(1):e30707. PubMed ID: 37814424
[TBL] [Abstract][Full Text] [Related]
18. Current standards of care in bladder and prostate rhabdomyosarcoma.
Kieran K; Shnorhavorian M
Urol Oncol; 2016 Feb; 34(2):93-102. PubMed ID: 26776454
[TBL] [Abstract][Full Text] [Related]
19. Clinical and mutational spectrum of highly differentiated, paired box 3:forkhead box protein o1 fusion-negative rhabdomyosarcoma: A report from the Children's Oncology Group.
Teot LA; Schneider M; Thorner AR; Tian J; Chi YY; Ducar M; Lin L; Wlodarski M; Grier HE; Fletcher CDM; van Hummelen P; Skapek SX; Hawkins DS; Wagers AJ; Rodriguez-Galindo C; Hettmer S
Cancer; 2018 May; 124(9):1973-1981. PubMed ID: 29461635
[TBL] [Abstract][Full Text] [Related]
20. From the archives of the AFIP. Genitourinary rhabdomyosarcoma in children: radiologic-pathologic correlation.
Agrons GA; Wagner BJ; Lonergan GJ; Dickey GE; Kaufman MS
Radiographics; 1997; 17(4):919-37. PubMed ID: 9225391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
